Mereo BioPharma: Neoplasms trials

The registry lists 11 Neoplasms studies with Mereo BioPharma as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 11Phase 2 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT04761198Phase 1/2Results posted
• A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic TumorsTerminatedNCT03295942Phase 1
• A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid TumorsCompletedNCT02722954Phase 1
• A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10CompletedNCT02482441Phase 1
• A Phase 1 Study of OMP-305B83 in Subjects With Solid TumorsCompletedNCT02298387Phase 1
• A Dose Escalation Study of OMP-52M51 in Subjects With Solid TumorsCompletedNCT01778439Phase 1
• A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid MalignanciesCompletedNCT01703572Phase 1
• A Dose Escalation Study of OMP-54F28 in Subjects With Solid TumorsCompletedNCT01608867Phase 1
• A Dose Escalation Study of OMP-18R5 in Subjects With Solid TumorsCompletedNCT01345201Phase 1
• A Dose Escalation Study of OMP-59R5 in Subjects With Solid TumorsCompletedNCT01277146Phase 1
• A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid TumorsCompletedNCT00744562Phase 1